127 related articles for article (PubMed ID: 33841639)
1. Identification and validation of significant gene mutations to predict clinical benefit of immune checkpoint inhibitors in lung adenocarcinoma.
Chen Y; Miao S; Zhao W
Am J Transl Res; 2021; 13(3):1051-1063. PubMed ID: 33841639
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
[TBL] [Abstract][Full Text] [Related]
5. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1647-1654. PubMed ID: 32342665
[TBL] [Abstract][Full Text] [Related]
7. Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.
Peng J; Zou D; Gong W; Kang S; Han L
Oncoimmunology; 2020; 9(1):1734156. PubMed ID: 32158626
[TBL] [Abstract][Full Text] [Related]
8. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
Kang K; Xie F; Mao J; Bai Y; Wang X
Front Oncol; 2020; 10():573141. PubMed ID: 33072607
[No Abstract] [Full Text] [Related]
9. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
Heeke S; Benzaquen J; Long-Mira E; Audelan B; Lespinet V; Bordone O; Lalvée S; Zahaf K; Poudenx M; Humbert O; Montaudié H; Dugourd PM; Chassang M; Passeron T; Delingette H; Marquette CH; Hofman V; Stenzinger A; Ilié M; Hofman P
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470674
[TBL] [Abstract][Full Text] [Related]
10. Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations.
Yang W; Chen N; Li L; Chen X; Liu X; Zhang Y; Cui J
Lung Cancer (Auckl); 2020; 11():59-71. PubMed ID: 32982525
[TBL] [Abstract][Full Text] [Related]
11. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer.
Zhao J; Wang L; Zhou A; Wen S; Fang W; Zhang L; Duan J; Bai H; Zhong J; Wan R; Sun B; Zhuang W; Lin Y; He D; Cui L; Wang Z; Wang J
Med; 2024 May; ():. PubMed ID: 38781965
[TBL] [Abstract][Full Text] [Related]
12. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
13. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
[No Abstract] [Full Text] [Related]
14. A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in
Xiang L; Fu X; Wang X; Li W; Zheng X; Nan K; Tian T
Front Oncol; 2020; 10():559896. PubMed ID: 33072585
[TBL] [Abstract][Full Text] [Related]
15. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
[TBL] [Abstract][Full Text] [Related]
17. Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy.
Wang L; Chu X; Yu X; Su C
Heliyon; 2024 Apr; 10(7):e27801. PubMed ID: 38560208
[TBL] [Abstract][Full Text] [Related]
18. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
19. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Max's Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors.
Qu Y; Wang C; Liu L; Li S; Zhang X; Ma Z; Bai H; Wang J
Front Cell Dev Biol; 2021; 9():728647. PubMed ID: 34733843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
